New advances in the management of children with intestinal failure

Journal of Parenteral and Enteral Nutrition

Volumn 36, Issue 1 SUPPL., 2012, Pages

  Peterson, Johann ^a   Kerner, John A ^a  

^a LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITRULLINE; FISH OIL; GATTEX; PLACEBO; TEDUGLUTIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LIPID; PEPTIDE;

CHILD; CONFERENCE PAPER; HUMAN; INTESTINAL FAILURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; BLOOD; INTESTINE; METHODOLOGY; PARENTERAL NUTRITION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT BOWEL SYNDROME; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CHILD; CITRULLINE; HUMANS; INTESTINES; LIPIDS; PARENTERAL NUTRITION; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHORT BOWEL SYNDROME; TREATMENT OUTCOME;

EID: 84860581411     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607111422069     Document Type: Conference Paper

References (64)

1. O'Keefe SJD, Buchman AL, Fishbein TM, et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4(1):6-10.
2. Koffeman GI, van Gemert WG, George EK, Veenendaal RA. Classification, epidemiology and aetiology. Best Pract Res Clin Gastroenterol. 2003;17(6):879-893.
3. Spencer AU, Kovacevich D, McKinney-Barnett M, et al. Pediatric short-bowel syndrome: the cost of comprehensive care. Am J Clin Nutr. 2008;88(6):1552-1559.
4. Goulet O, Baglin-Gobet S, Talbotec C, et al. Outcome and longterm growth after extensive small bowel resection in the neonatal period: a survey of 87 children. Eur J Pediatr Surg. 2005;15(2):95-101.
5. Goday PS. Short bowel syndrome: how short is too short? Clin Perinatol. 2009;36(1):101-110.
6. Wales P. Neonatal short bowel syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg. 2004;39(5):690-695.
7. Quirós-Tejeira RE, Ament ME, Reyen L, et al. Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience. J Pediatr. 2004;145(2):157-163.
8. Diamond IR, de Silva N, Pencharz PB, Kim JH, Wales PW. Neonatal short bowel syndrome outcomes after the establishment of the first Canadian multidisciplinary intestinal rehabilitation program: preliminary experience. J Pediatr Surg. 2007;42(5):806-811.
9. Wales PW, de Silva N, Kim JH, et al. Neonatal short bowel syndrome: a cohort study. J Pediatr Surg. 2005;40(5):755-762.
10. Vantini I, Benini L, Bonfante F, et al. Survival rate and prognostic factors in patients with intestinal failure. Dig Liver Dis. 2004;36(1):46-55.
11. Sondheimer JM, Cadnapaphornchai M, Sontag M, Zerbe GO. Predicting the duration of dependence on parenteral nutrition after neonatal intestinal resection. J Pediatr. 1998;132(1):80-84.
12. Spencer AU, Neaga A, West B, et al. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg. 2005;242(3): 403-409.
13. Diamond IR, Struijs M-C, de Silva NT, Wales PW. Does the colon play a role in intestinal adaptation in infants with short bowel syndrome? A multiple variable analysis. J Pediatr Surg. 2010;45(5): 975-979.
14. Peters JHC, Beishuizen A, Keur MB, et al. Assessment of small bowel function in critical illness: potential role of citrulline metabolism. J Intensive Care Med. 2011;26(2):105-110.
15. Papadia C, Sherwood RA, Kalantzis C, et al. Plasma citrulline concentration: a reliable marker of small bowel absorptive capacity independent of intestinal inflammation. Am J Gastroenterol. 2007;102(7):1474-1482.
16. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr. 2008;27(3):328-339.
17. Diamanti A, Panetta F, Gandullia P, et al. Plasma citrulline as marker of bowel adaptation in children with short bowel syndrome. Langenbecks Arch Surg. 2011;396(7):1041-1046.
18. Bailly-Botuha C, Colomb V, Thioulouse E, et al. Plasma citrulline concentration reflects enterocyte mass in children with short bowel syndrome. Pediatr Res. 2009;65(5):559-563.
19. Crenn P, Coudray-Lucas C, Thuillier F, Cynober L, Messing B. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology. 2000;119(6):1496-1505.
20. Jianfeng G, Weiming Z, Ning L, et al. Serum citrulline is a simple quantitative marker for small intestinal enterocytes mass and absorption function in short bowel patients. J Surg Res. 2005;127(2): 177-182.
21. Rhoads JM, Plunkett E, Galanko J, et al. Serum citrulline levels correlate with enteral tolerance and bowel length in infants with short bowel syndrome. J Pediatr. 2005;146(4):542-547.
22. Khan M, Miserachs M, Hofmeister B, et al. Degree of parenteral nutrition support correlates with serum citrulline levels in short bowel syndrome. JPEN J Parenter Enteral Nutr. 2010;35:131-139.
23. Luo M, Fernández-Estívariz C, Manatunga AK, et al. Are plasma citrulline and glutamine biomarkers of intestinal absorptive function in patients with short bowel syndrome? JPEN J Parenter Enteral Nutr. 2007;31(1):1-7.
24. Fitzgibbons S, Ching YA, Valim C, et al. Relationship between serum citrulline levels and progression to parenteral nutrition independence in children with short bowel syndrome. J Pediatr Surg. 2009;44(5):928-932.
25. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224-1231.
26. Jeppesen PB, Hartmann B, Hansen BS, et al. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure. Gut. 1999;45(4): 559-563.
27. Jeppesen PB, Hartmann B, Thulesen J, et al. Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut. 2000;47(3): 370-376.
28. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996;93(15):7911-7916.
29. Stevens FM, Flanagan RW, O'Gorman D, Buchanan KD. Glucagonoma syndrome demonstrating giant duodenal villi. Gut. 1984;25(7):784-791.
30. Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut. 1971;12(10):773-782.
31. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902-914.
32. NPS Pharmaceuticals. Gattex (teduglutide) meets primary efficacy endpoint in phase 3 pivotal study in patients with adult short bowel syndrome [press release]. http://www.npsp.com/PressReleases/1521514. Accessed June 15, 2011.
33. Allardyce DB. Cholestasis caused by lipid emulsions. Surg Gynecol Obstet. 1982;154(5):641-647.
34. Colomb V, Jobert-Giraud A, Lacaille F, et al. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr. 2000;24(6):345-350.
35. Shin JI, Namgung R, Park MS, Lee C. Could lipid infusion be a risk for parenteral nutrition-associated cholestasis in low birth weight neonates? Eur J Pediatr. 2008;167(2):197-202.
36. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000;132(7):525-532.
37. Fallon EM, Le HD, Puder M. Prevention of parenteral nutritionassociated liver disease: role of omega-3 fish oil. Curr Opin Organ Transplant. 2010;15(3):334-340.
38. de Meijer VE, Gura KM, Le HD, Meisel JA, Puder M. Fish oilbased lipid emulsions prevent and reverse parenteral nutritionassociated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr. 2009;33(5):541-547.
39. Gura KM, Lee S, Valim C, et al. Safety and efficacy of a fish-oilbased fat emulsion in the treatment of parenteral nutritionassociated liver disease. Pediatrics. 2008;121(3):e678-e686.
40. Puder M, Valim C, Meisel JA, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg. 2009;250(3):395-402.
41. Diamond IR, Sterescu A, Pencharz PB, Kim JH, Wales PW. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr. 2009;48(2):209-215.
42. Cheung HM, Lam HS, Tam YH, Lee KH, Ng PC. Rescue treatment of infants with intestinal failure and parenteral nutritionassociated cholestasis (PNAC) using a parenteral fish-oil-based lipid. Clin Nutr. 2009;28(2):209-212.
43. Chung PHY, Wong KKY, Wong RMS, et al. Clinical experience in managing pediatric patients with ultra-short bowel syndrome using omega-3 fatty acid. Eur J Pediatr Surg. 2010;20(2):139-142.
44. Malone FR, Javid PJ, Davis C, et al. Omega-3 Fatty acid supplementation normalizes bilirubin in cholestatic children dependent on parenteral nutrition. J Pediatr Gastroenterol Nutr. 2009;49 (Suppl 1):E38-E39. Presented at: North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting, November 12-14, 2009; National Harbor, Maryland.
45. Calhoun AW, Sullivan JE. Omegaven for the treatment of parenteral nutrition associated liver disease: a case study. J Ky Med Assoc. 2009;107(2):55-57.
46. Ekema G, Falchetti D, Boroni G, et al. Reversal of severe parenteral nutrition-associated liver disease in an infant with short bowel syndrome using parenteral fish oil (omega-3 fatty acids). J Pediatr Surg. 2008;43(6):1191-1195.
47. Soden JS, Lovell MA, Brown K, Partrick DA, Sokol RJ. Failure of resolution of portal fibrosis during omega-3 fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. J Pediatr. 2010;156(2):327-331.
48. Fitzgibbons SC, Jones BA, Hull MA, et al. Relationship between biopsy-proven parenteralnutrition-associated liver fibrosis and biochemical cholestasis in children with short bowel syndrome. J Pediatr Surg. 2010;45(1):95-99.
49. Park KT, Nespor C, Kerner J Jr. The use of Omegaven in treating parenteral nutrition-associated liver disease. J Perinatol. 2011;31(suppl 1):S57-S60.
50. Goulet O, Antébi H, Wolf C, et al. A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2010;34(5): 485-495.
51. Tomsits E, Pataki M, Tölgyesi A, et al. Safety and efficacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil: a randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J Pediatr Gastroenterol Nutr. 2010;51(4):514-521.
52. Strijbosch RAM, Lee S, Arsenault DA, et al. Fish oil prevents essential fatty acid deficiency and enhances growth: clinical and biochemical implications. Metabolism. 2008;57(5):698-707.
53. de Meijer VE, Le HD, Meisel JA, Gura KM, Puder M. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr. 2010;50(2):212-218.
54. Cober MP, Teitelbaum DH. Prevention of parenteral nutritionassociated liver disease: lipid minimization. Curr Opin Organ Transplant. 2010;15(3):330-333.
55. Nasr A, Diamond IR, de Silva NT, Wales PW. Is the use of parenteral omega-3 lipid emulsions justified in surgical neonates with mild parenteral nutrition-associated liver dysfunction? J Pediatr Surg. 2010;45(5):980-986.
56. Dannenberg C, Bierbach U, Rothe A, Beer J, Körholz D. Ethanollock technique in the treatment of bloodstream infections in pediatric oncology patients with broviac catheter. J Pediatr Hematol Oncol. 2003;25(8):616-621.
57. Broom J, Woods M, Allworth A, et al. Ethanol lock therapy to treat tunnelled central venous catheter-associated blood stream infections: results from a prospective trial. Scand J Infect Dis. 2008;40(5):399-406.
58. Onland W, Shin CE, Fustar S, Rushing T, Wong W-Y. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch Pediatr Adolesc Med. 2006;160(10):1049-1053.
59. Mouw E, Chessman K, Lesher A, Tagge E. Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome. J Pediatr Surg. 2008;43(6):1025-1029.
60. Jones BA, Hull MA, Richardson DS, et al. Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure. J Pediatr Surg. 2010;45(6):1287-1293.
61. Opilla MT, Kirby DF, Edmond MB. Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients. JPEN J Parenter Enteral Nutr. 2007;31(4):302-305.
62. Cober MP, Kovacevich DS, Teitelbaum DH. Ethanol-lock therapy for the prevention of central venous access device infections in pediatric patients with intestinal failure. JPEN J Parenter Enteral Nutr. 2011;35(1):67-73.
63. Wales PW, Kosar C, Carricato M, et al. Ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients with intestinal failure: preliminary experience. J Pediatr Surg. 2011;46(5):951-956.
64. Pieroni K, Nespour C, Ng M, Berquist W, Kerner J. Evaluation of ethanol lock therapy in pediatric patients on long-term parenteral nutrition. Presented at: Pediatric Academic Societies and Asian Society or Pediatric Research 2011 Joint Meeting, 2011; Denver, CO. Available at: http://www.abstracts2view.com/ pas/view.php?nu=PAS11L1-507.